Information Provided By:
Fly News Breaks for May 31, 2016
PTLA
May 31, 2016 | 07:12 EDT
Credit Suisse analyst Vamil Divan downgraded Portola Pharmaceuticals to Neutral and lowered its price target to $30 from $33 citing the recent recovery in shares and more conservative estimates around the uptake of andexanet alfa following a series of conversations with experts in the field.
News For PTLA From the Last 2 Days
There are no results for your query PTLA